• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Rituxan hits endpoints in late-stage skin disease trial pharmatimes
    June 16, 2019
    Roche has announced that its monoclonal antibody, Rituxan (rituximab), met all primary and secondary endpoints in the Phase III PEMPHIX study.
  • Zerbaxa Meets Primary Endpoints americanpharmaceuticalreview
    September 12, 2018
    Merck announced the pivotal Phase 3 clinical study evaluating the company’s antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP)
  • Ionis Announces Phase 3 NEURO-TTR Study of Inotersen Meets Primary Endpoints americanpharmaceuticalreview
    May 16, 2017
    Ionis Pharmaceuticals announced the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service